| 2014 Accounts |
|
|
| |
|
|
| Acknowledgement of Financial Support (1) |
| |
|
% of total income |
| EPF wishes to thank the European Commission for its support in 2014 in relation to EPF's role in the following projects: |
|
|
| Renewing Health |
3,000.00 € |
0.2% |
| Sustains |
23,681.00 € |
1.4% |
| JA PASQ |
48,560.40 € |
2.9% |
| JA Chronic Diseases |
30,498.60 € |
1.8% |
| Cross Border Health Care Conference |
53,355.71 € |
3.2% |
| Empathie |
36,062.36 € |
2.2% |
| Interquality |
41,566.00 € |
2.5% |
| |
|
|
| |
|
|
| EPF wishes to thank the following donors for their support: |
| |
|
|
| Operational work programme |
|
|
| European Commission (Executive Agency for Health and Consumers) |
653,966.00 € |
39.1% |
| Baxter World Trade |
10,000.00 € |
0.6% |
| GSK |
30,000.00 € |
1.8% |
| Janssen |
16,500.00 € |
1.0% |
| Merck Sharp & Dohme |
30,000.00 € |
1.8% |
| Novartis |
30,000.00 € |
1.8% |
| Pfizer |
20,000.00 € |
1.2% |
| Sanofi-Aventis |
20,000.00 € |
1.2% |
| Note: The donors contribute as follows: European Commission: 80%; industry donors 19,1%; membership fees 0,9% |
| |
|
|
| Project portfolio and capacity building programme |
|
| Abbvie |
25,000.00 € |
1.5% |
| AMGEN |
35,000.00 € |
2.1% |
| Biogen IDEC International GmbH |
20,000.00 € |
1.2% |
| CSL Behring Biotherapies |
10,000.00 € |
0.6% |
| Gilead |
20,000.00 € |
1.2% |
| GSK |
50,000.00 € |
3.0% |
| Grünenthal GmbH |
10,000.00 € |
0.6% |
| Hoffmann-La Roche |
15,000.00 € |
0.9% |
| Hospira Benelux BVBA |
25,000.00 € |
1.5% |
| Janssen Pharmaceutica |
13,500.00 € |
0.8% |
| Laboratoires Servier |
10,000.00 € |
0.6% |
| Novartis |
20,000.00 € |
1.2% |
| Pfizer |
20,000.00 € |
1.2% |
| S.A. Eli Lilly Benelux N.V |
15,000.00 € |
0.9% |
| Sanofi-Aventis |
40,000.00 € |
2.4% |
| Shire |
5,000.00 € |
0.3% |
| |
|
|
| The European Patients' Academy on Therapeutic Innovation Public Private Partnership (EUPATI) |
|
|
| Innovative Medicine Initiative (IMI JU) contribution |
171,114.05 € |
10.2% |
| Industry consortium (Hoffman La Roche, Genzyme, Boehringer, VFA, GSK, AMGEN, ESTVE, Novonordis, S.A. Eli Lilly, Novartis, Astra Zeneca, Bayer, UCB, CHIESI, Janssen, Merck) |
78,777.00 € |
4.7% |
| |
|
|
| Note: the income provided represents EPF's share in the consortium's contributions to the project only. |
| |
|
|
| Memberships and other income |
43,832.21 € |
2.6% |
| |
|
|
| Total income |
1,674,413.33 € |
100.0% |
| |
|
|
| Accruals and deferrals (1) |
-80,630.09 € |
|
| |
|
|
| Total income net of adjustments |
1,593,783.24 € |
|
| |
|
|
| (1) In accordance with generally accepted accounting principles, funding received in-year is subject to accrual and deferral adjustments proportionate to the level of resources assigned to pluriannual activities and projects. In 2014, this method had the effect of a decrease of total income by € 80.630,09 |
| |
|
|
